Company intelligence / Profile preview

Rarecells

Paris, Île-de-France, Francerarecells.com ↗

Ownership: Private
Development stage: Other

Overview

Rarecells has developed the ISET® liquid biopsy platform, which enables non-invasive early detection of cancer by isolating and analyzing circulating tumor cells from blood. The technology has CE-IVD certification in Europe and over a decade of validation with more than 125 independent publications. Ongoing clinical studies are evaluating its sensitivity for early lung cancer detection and recurrence monitoring. The company’s approach allows label-free access to intact CTCs and their DNA for downstream molecular analysis.

Therapeutic areas: Women's HealthHematologyOncology
Modalities: Device (liquid biopsy platform)Diagnostic test (blood-based)Molecular diagnostic technology
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Rarecells.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rarecells.

Explore the full profile